Coronavirus Vaccine: Bangavax and two other vaccines to meet human trial conditions
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Tuesday
July 08, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
TUESDAY, JULY 08, 2025
Bangavax and two other vaccines to meet human trial conditions

Covid-19 in Bangladesh

TBS Report
16 June, 2021, 02:15 pm
Last modified: 16 June, 2021, 08:46 pm

Related News

  • Bangavax gets DGDA nod for human trials
  • Globe Biotech publishes Bangavax results of tests on monkeys
  • Indian Covaxin to be permitted for trial in Bangladesh
  • TBS Today: Bangavax trials face scientific and ethical concerns
  • NZ regulator approves Pfizer vaccine for 12-15 year olds

Bangavax and two other vaccines to meet human trial conditions

Globe Biotech and two Indian and Chinese drugmakers must submit documents on the effectiveness and side effects of the vaccines on monkeys

TBS Report
16 June, 2021, 02:15 pm
Last modified: 16 June, 2021, 08:46 pm
Logo of Globe Biotech Limited. Picture: Collected
Logo of Globe Biotech Limited. Picture: Collected

The Bangladesh Medical Research Council (BMRC) has set conditions for the human trial of three more coronavirus vaccines, including local drugmaker Globe Biotech's Bangavax, and two others from China and India respectively.

Before "human trials", the institutes will have to fulfil all conditions as per BMRC rules.

The decision was made at a meeting of the National Research Ethics Committee of the BMRC on Wednesday morning.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"We have decided in principle to approve the three vaccines. But they must meet certain conditions," BMRC Director, Professor Dr Ruhul Amin, told journalists after the meeting.

"All documents on the effectiveness and side effects of these vaccines on monkeys or chimpanzees must be submitted to the BMRC prior to Phase-1 trials. The issue of safety in human use will be seriously considered. If these rules are followed, we will definitely approve."

In addition to Bangavax, it has been decided in principle to approve the applications of Bharat Biotech and the Vero cell vaccine by the Institute of Medical Biology, Chinese Academy of Medical Sciences.

Two icddr,b scientists sought approval for the Chinese and Indian vaccines, and Globe Biotech for Bangavax.

Dr Ruhul Amin said, "It is not that the Globe vaccine has received approval for a clinical trial. But we are positive, even though several issues have been raised, including safety issues."

He said the three companies that have applied for first and second phase clinical trials will be informed of the Bangladesh Medical Research Council's (BMRC) decision.

"If necessary, the Contract Research Organisations (CROs) of the three companies can be called at any time to know the current status of the institutes," he added.

On 28 December, Globe Biotech, a Bangladeshi biotech firm, got approval from the Directorate General of Drug Administration (DGDA) to produce Covid-19 vaccine candidate Bangavax to carry out clinical trials.

On 16 January it submitted its trial protocol to the BMRC for the clinical trials of its Covid-19 vaccine, Bangavax.

Earlier, the company on 5 October 2020, noted that vaccine trials on rabbits and mice had shown "very promising results."

Bangladesh has so far approved the emergency use of six vaccines – Oxford-AstraZeneca, Sinopharm of China, Sputnik-V of Russia, Pfizer-BioNTech, CronaVac of China, and Johnson & Johnson.

Bangladesh / Top News

BMRC / conditonally / approves / human trial / Bangavax

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Representational image. Photo: TBS
    35% US tariff to be disastrous for Bangladesh's exports, say economists and exporters
  • Graph: Reuters
    Trump sends letter to Yunus imposing 35% tariff on Bangladeshi products
  • Chinese Ambassador to Bangladesh Yao Wen pays courtesy call on the leaders of BNP at the party chairperson's office in Gulshan, Dhaka, on 8 July 2025. Photo: Courtesy
    Chinese ambassador pays courtesy call on BNP leaders

MOST VIEWED

  • The Mitsubishi Xpander is built with families in mind, ready to handle the daily carpool, grocery runs, weekend getaways, and everything in between. PHOTO: Akif Hamid
    Now made-in-Bangladesh: 2025 Mitsubishi Xpander
  • Illustration: Ashrafun Naher Ananna/TBS Creative
    World’s largest container shipping companies
  • Representational image
    Dhaka gets relief as Trump pushes tariff deadline to 1 Aug
  • A quieter scene at Dhaka University’s central library on 29 June, with seats still unfilled—unlike earlier this year, when the space was overwhelmed by crowds of job aspirants preparing for competitive exams. Photo: Tahmidul Alam Jaeef
    No more long queues at DU Central Library. What changed?
  • Illustration: Duniya Jahan/TBS Creative
    Inflation drops below 9% after 27 months
  • Illustration: Duniya Jahan/TBS Creative
    Young population believe BNP to get 39% of votes, Jamaat 21%, NCP 16% in national polls: Sanem survey

Related News

  • Bangavax gets DGDA nod for human trials
  • Globe Biotech publishes Bangavax results of tests on monkeys
  • Indian Covaxin to be permitted for trial in Bangladesh
  • TBS Today: Bangavax trials face scientific and ethical concerns
  • NZ regulator approves Pfizer vaccine for 12-15 year olds

Features

Dr Mostafa Abid Khan. Sketch: TBS

Actual impact will depend on how US retailers respond: Mostafa Abid Khan

1h | Economy
Thousands gather to form Bangla Blockade in mass show of support. Photo: TBS

Rebranding rebellion: Why ‘Bangla Blockade’ struck a chord

17h | Panorama
The Mitsubishi Xpander is built with families in mind, ready to handle the daily carpool, grocery runs, weekend getaways, and everything in between. PHOTO: Akif Hamid

Now made-in-Bangladesh: 2025 Mitsubishi Xpander

1d | Wheels
Students of different institutions protest demanding the reinstatement of the 2018 circular cancelling quotas in recruitment in government jobs. Photo: Mehedi Hasan

5 July 2024: Students announce class boycott amid growing protests

3d | Panorama

More Videos from TBS

Trump imposes 35% tariff on Bangladeshi products

Trump imposes 35% tariff on Bangladeshi products

2h | TBS World
Much of Iran’s Military Capacities Still Unutilized, General Warns Israel

Much of Iran’s Military Capacities Still Unutilized, General Warns Israel

15h | TBS World
How Trump's tariff chaos could reshape Asia's businesses

How Trump's tariff chaos could reshape Asia's businesses

5h | Others
How will Europe stop Russia's Shadow Fleet?

How will Europe stop Russia's Shadow Fleet?

15h | Others
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net